This article is more than 5 years old. Information may no longer be current.

VIDEO: Mel Spigelman, MD, discusses TB drug pipeline

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — Mel Spigelman, MD, president and CEO of TB Alliance, discusses the drug development pipeline for tuberculosis here at ASM Microbe 2016. He said that many of the new drugs and regimens developed over the past few years show promise against multidrug-resistant TB, but that novel treatments are still necessary.

“We still need a lot more work, and many more new compounds that will eventuate into much better therapeutics,” he said.

Disclosure: Spigelman reports no relevant financial disclosures.